Cipla Health Launches Omnigel Maxstrong, Expands Pain Relief Portfolio with New 2% Diclofenac Formula

Omnigel Introduces a New Pain Relief Product

Cipla Health has announced the launch of Omnigel Maxstrong, the latest addition to its Omnigel pain relief range.

With this launch, Omnigel enters the growing 2% diclofenac category, which is becoming a popular choice in pain management. The company says the new product is designed to offer stronger and longer-lasting pain relief for people who experience muscle and joint pain as part of their daily routine.

Designed for Everyday Muscle and Joint Pain

Omnigel Maxstrong is developed for people who regularly deal with muscle aches, joint pain, and body discomfort caused by an active lifestyle or everyday activities.

According to Cipla Health, the new formulation delivers 5X Action and long-lasting relief, helping people stay active and continue with their daily routines more comfortably.

The product is intended to support effective pain management without interrupting everyday movement.

Omnigel Enters the 2% Diclofenac Segment

The launch is an important step for the Omnigel brand as it expands into the evolving 2% diclofenac category.

Diclofenac is a well-known anti-inflammatory medicine commonly used to reduce pain and swelling in muscles and joints. The 2% diclofenac formulation is increasingly being adopted across the industry as an advanced option for topical pain relief.

With Omnigel Maxstrong, Cipla Health is strengthening its presence in this growing segment.

First Omnigel Sub-Brand Introduced

The launch of Omnigel Maxstrong also marks another milestone for the brand.

This is the first time Omnigel has introduced a dedicated sub-brand. Along with the new product, the company has also unveiled a refreshed packaging design that gives the brand a more modern and premium appearance.

While the packaging has been updated, it continues to feature Omnigel's familiar red color palette and key pain relief elements, helping consumers easily recognize the brand.

Available in Gel and Spray Formats

Omnigel Maxstrong will be offered in both gel and spray formats to suit different user preferences.

The gel is available in a 30 gm pack, while the spray comes in four pack sizes:

• 35 gm
• 55 gm
• 75 gm
• 100 gm

By introducing multiple formats and pack sizes, Cipla Health aims to give consumers more flexibility in choosing the product that best fits their needs.

Omnigel Continues to Expand Its Pain Relief Range

With the launch of Omnigel Maxstrong, Cipla Health is further expanding its pain relief portfolio.

The company says the new product supports its ongoing focus on providing effective pain management solutions that help people stay active and maintain movement in their everyday lives.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!